SARS-COV-2: is it a risk for blood transfusion?

Langhi, Dante Mário; Souza, Ricardo Cartaxo Modesto de; Barros, Melca Maria Oliveira; Santis, Gil Cunha De; Kashima, Simone; Bordin, José Orlando

doi:10.1016/j.htct.2021.08.001

Cited by 6 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For donors infected with SARS-CoV-2, multiple sources, including the U.S. FDA and other authors both in Korea and abroad, state that the possibility of SARS-CoV-2 transmitted by blood is low and has not been reported in the literature. Nevertheless, standard care procedures should still be taken [15][16][17][18], but the current literature includes mostly case reports. Further large-scale studies assessing the safety of blood donation by people infected with SARS-CoV-2 are warranted.…”

Section: Discussionmentioning

confidence: 99%

Three Cases of SARS-CoV-2 Infection with Cold Antibody of Undetermined Specificity in Antibody Screening in Transfusion Labs

Kim

Shin

Hong

et al. 2022

Korean J Blood Transfus

View full text Add to dashboard Cite

SARS-CoV-2 infections continue to occur in this worldwide pandemic and have been associated with various symptoms, including autoimmune disorders. Of the latter, several reports of SARS-CoV-2-associated cold-agglutinin syndrome (CAS) have been published. CAS is associated with other viral infections, such as that by the Epstein-Barr virus. This paper reports a case series of SARS-CoV-2-associated cold-agglutinin syndrome presenting as an antibody of undetermined specificity mainly reactive at cold temperatures and mostly detected as C3d, but sometimes as IgM on the direct antiglobulin test.

show abstract

Section: Discussionmentioning

confidence: 99%

Three Cases of SARS-CoV-2 Infection with Cold Antibody of Undetermined Specificity in Antibody Screening in Transfusion Labs

Kim

Shin

Hong

et al. 2022

Korean J Blood Transfus

View full text Add to dashboard Cite

show abstract

“…Similar to other human coronaviruses (including SARS-CoV and Middle East respiratory syndrome CoV), TT of SARS-CoV-2 has not been reported, despite 251 million reported confirmed cases globally as at 11 November 2021 [ 103 , 104 ]. There have been several reports of transfusion of blood products (PLTs, red blood cell [RBCs], and granulocyte concentrate) from donors who were subsequently diagnosed with SARS-CoV-2 infection (Table 2 ) [ 84 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 ]. In all reported cases, including at least three donors who had detectable RNAaemia at time of donation [ 84 , 105 ], there was no evidence of TT of SARS-CoV-2 to recipients.…”

Section: Sars-cov-2: Implications For Blood Safety and Sufficiencymentioning

confidence: 99%

“…In all reported cases, including at least three donors who had detectable RNAaemia at time of donation [ 84 , 105 ], there was no evidence of TT of SARS-CoV-2 to recipients. One recipient tested SARS-CoV-2 antibody positive, but time of infection was uncertain, other modes of transmission could not be excluded, and given the donor became symptomatic 4 days post-donation, it is very unlikely to be related to the transfusion [ 110 ]. There has been a reported case of SARS-CoV-2 transmission to recipient of a lung transplant from an infected donor with transmission confirmed by genomic sequencing [ 114 ].…”

Section: Sars-cov-2: Implications For Blood Safety and Sufficiencymentioning

confidence: 99%

“…[103,104]. There have been several reports of transfusion of blood products ( PLTs, red blood cell [RBCs], and granulocyte concentrate) from donors who were subsequently diagnosed with SARS-CoV-2 infection (Table 2) [84,[105][106][107][108][109][110][111][112][113]. In all reported cases, including at least three donors who had detectable RNAaemia at time of donation [84,105], there was no evidence of TT of SARS-CoV-2 to recipients.…”

Section: Transfusion-transmissibilitymentioning

confidence: 99%

See 1 more Smart Citation

Severe Acute Respiratory Syndrome Coronavirus 2 and Blood Safety: An Updated Review

Kiely

Hoad

Seed

et al. 2022

Transfus Med Hemother

View full text Add to dashboard Cite

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel human coronavirus first identified in late 2019 and subsequently declared a worldwide pandemic in March 2020. In this review, we provide an overview of the implications of SARS-CoV-2 for blood safety and sufficiency. Summary: Approximately one-third of SARS-CoV-2 infections are asymptomatic. The reported mean incubation period typically varies from 2 to 11 days, but longer periods up to 22 days have been reported. The blood phase of SARS-CoV-2 appears to be brief and low level, with RNAaemia detectable in only a small proportion of patients, typically associated with more severe disease and not demonstrated to be infectious virus. A small number of presymptomatic and asymptomatic blood phase cases have been reported. Transfusion-transmission (TT) of SARS-CoV-2 has not been reported. Therefore, the TT risk associated with SARS-CoV-2 is currently theoretical. To mitigate any potential TT risk, but more importantly to prevent respiratory transmission in donor centers, blood services can implement donor deferral policies based on travel, disease status, or potential risk of exposure and encourage staff vaccination. Key Messages: The TT risk of SARS-CoV-2 appears to be low. The biggest risk to blood services in the current COVID-19 pandemic is to maintain the sufficiency of the blood supply while minimizing respiratory transmission of SARS-CoV-2 to donors and staff while donating blood.

show abstract

“…Preventative measure procedures are advised, such as avoiding blood donation for 21 days after any probable exposure to individuals with confirmed Covid-19 infection, and people recovering fromCovid-19 should avoid donating blood for at least 28 days after their symptoms have resolved [43].…”

Section: Covid-19 Protective Measures To Undertake During Blood Trans...mentioning

confidence: 99%

Blood Transmission of Corona Virus Disease 2019. Are there any Threat?

Sabri¹,

MS²

2022

annhematoloncol

View full text Add to dashboard Cite

Background: Corona Virus infection is rapidly expanding and has a significant worldwide influence on the status of health and the economic process. Aim: Performing a literature search to investigate possible impacts of transmission of COVID-19 disease through blood transfusion process in health care system, and disease prevalence. Methods: Internet search in scientific publications and collecting data regarding different viral transmission routes, viral detection and disease diagnosis methods, what are the potential problems and risks in COVID-19 management, and COVID-19 protective measures to undertake during blood transfusion. Discussion and Conclusion: Coronavirus spreads mostly by droplets produced by infected persons while coughing, sneezing, or speaking. Different Covid-19 diagnosis methods include Computed Tomography (CT) scan, reverse transcription-polymerase chain reaction, antibody testing (IgG, and IgM), and biochemical tests. Different disease management risks may occur including antibiotic resistance, occupational stress, immune function suppression or dysregulation, pharmacodynamic interactions like prolongation of the QT interval. Although the findings indicated that blood transfusion did not transmitted coronavirus, but protective measures should be undertaken during blood transfusion process in healthcare facilities and blood transfusion centers. This will aid in mitigating viral transmission and associated management risks that may occur.

show abstract

SARS-COV-2: is it a risk for blood transfusion?

Cited by 6 publications

References 8 publications

Three Cases of SARS-CoV-2 Infection with Cold Antibody of Undetermined Specificity in Antibody Screening in Transfusion Labs

Three Cases of SARS-CoV-2 Infection with Cold Antibody of Undetermined Specificity in Antibody Screening in Transfusion Labs

Severe Acute Respiratory Syndrome Coronavirus 2 and Blood Safety: An Updated Review

Blood Transmission of Corona Virus Disease 2019. Are there any Threat?

Contact Info

Product

Resources

About